423 results
424B5
LCTX
Lineage Cell Therapeutics, Inc.
14 May 24
Prospectus supplement for primary offering
4:36pm
of Neurosurgery Spine. OPC1 clinical development has been supported in part by a $14.3 million grant from the California Institute for Regenerative Medicine
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics, Inc.
9 May 24
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:10pm
start-up activities underway.
oReceived an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM), to support … , 2024 at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
-Corporate Updates
oAppointed veteran industry executive Dr. Charlotte
424B5
LCTX
Lineage Cell Therapeutics, Inc.
22 Mar 24
Prospectus supplement for primary offering
4:32pm
for Regenerative Medicine. In March 2024, we received written correspondence from the U.S. Food and Drug Administration (“FDA”) regarding our … has been partially funded by the California Institute for Regenerative Medicine.
VAC2, an allogeneic cancer immunotherapy of antigen-presenting
424B5
cg0tx9qcg5vypm5 rbgf
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-99.1
r2fb8a4p5l6w
11 May 23
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm
8-K
EX-99.1
13izp svhuyz
10 Nov 22
LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:11pm
8-K
EX-99.1
zait5o6
11 Aug 22
LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm